====== Helen Groves ======

Dr. **Helen E. Groves**, MB, BCh, BAO, PhD is a Canadian infectious diseases specialist based in [[canada:ontario:Toronto]], [[canada:Ontario]].

===== Career and Affiliations =====

==== SickKids ====

Groves is employed by [[SickKids]] in the Division of Infectious Diseases.((Groves, H. E., Papenburg, J., Mehta, K., Bettinger, J. A., Sadarangani, M., Halperin, S., & Morris, S. (2021). //1188. The Effect Of The COVID-19 Pandemic On Influenza-Related Hospitalization, Intensive Care Admission And Mortality In Canadian Children.// Open Forum Infectious Diseases, 8(Supplement_1), S685–S686. https://doi.org/10.1093/ofid/ofab466.1380)) ((Bruno, V., Tjon, J., Lin, S., Groves, H., Kazmi, K., Zappitelli, M., & Harvey, E. (2021). //Peritoneal dialysis-related peritonitis caused by Gordonia bronchialis: first pediatric report.// Pediatric Nephrology, 37(1), 217–220. https://doi.org/10.1007/s00467-021-05313-3))

==== University of Toronto ====

Groves works in the Department of Paediatrics at the [[University of Toronto]].((Bruno, V., Tjon, J., Lin, S., Groves, H., Kazmi, K., Zappitelli, M., & Harvey, E. (2021). //Peritoneal dialysis-related peritonitis caused by Gordonia bronchialis: first pediatric report.// Pediatric Nephrology, 37(1), 217–220. https://doi.org/10.1007/s00467-021-05313-3))

==== Ontario COVID-19 Science Advisory Table ====

Groves is an observer of the Drugs & Biologics Clinical Practice Guidelines Working Group of the [[Ontario COVID-19 Science Advisory Table]].((//About Us.// Ontario COVID-19 Science Advisory Table. Retrieved April 28, 2022, from https://covid19-sciencetable.ca/about/))

===== Research =====

==== Remdesivir ====

Groves was an author on a study on [[remdesivir]], funded by [[pharmaceutical_companies:Gilead Sciences]] and the [[National Institutes of Health]] (NIH), paid to the institutions of her colleagues.((Chiotos, K., Hayes, M., Kimberlin, D. W., Jones, S. B., James, S. H., Pinninti, S. G., Yarbrough, A., Abzug, M. J., MacBrayne, C. E., Soma, V. L., Dulek, D. E., Vora, S. B., Waghmare, A., Wolf, J., Olivero, R., Grapentine, S., Wattier, R. L., Bio, L., Cross, S. J., & Dillman, N. O. (2020). //Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2.// Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piaa115)) It was funded by the [[Agency for Healthcare Research and Quality]].

The study was also facilitated by the [[Sharing Antimicrobial Reports for Pediatric Stewardship]] (SHARPS) Collaborative, which is sponsored by [[medical_technology_companies:BioFire Diagnostics]] (a [[pharmaceutical_companies:BioMérieux]] company), [[medical_technology_companies:Cepheid]], [[pharmaceutical_companies:Evivo]], [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Horizon Pharma]], [[medical_technology_companies:Magnolia Medical Technologies]], [[pharmaceutical_companies:Roche]] and [[medical_technology_companies:VigiLanz]].((//Conference Sponsors.// SHARPS. Retrieved May 9, 2022, from https://web.archive.org/web/20220509075141/http://pediatrics.wustl.edu/sharps/Annual-Conference/Sponsors))

==== Influenza ====

Groves published research on the impact of [[COVID-19]] on [[influenza]].((Groves, H. E., Piché-Renaud, P.-P., Peci, A., Farrar, D. S., Buckrell, S., Bancej, C., Sevenhuysen, C., Campigotto, A., Gubbay, J. B., & Morris, S. K. (2021). //The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: A population-based study.// The Lancet Regional Health - Americas, 1, 100015. https://doi.org/10.1016/j.lana.2021.100015))

===== Relationship with pharmaceutical companies =====

Groves received honoraria from [[pharmaceutical_companies:AbbVie]].((Groves, H. E., Papenburg, J., Mehta, K., Bettinger, J. A., Sadarangani, M., Halperin, S., & Morris, S. (2021). //1188. The Effect Of The COVID-19 Pandemic On Influenza-Related Hospitalization, Intensive Care Admission And Mortality In Canadian Children.// Open Forum Infectious Diseases, 8(Supplement_1), S685–S686. https://doi.org/10.1093/ofid/ofab466.1380))